Homart Pharmaceuticals Pty Ltd Revenue and Competitors

RYDALMERE, AU

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Homart Pharmaceuticals Pty Ltd's estimated annual revenue is currently $23.3M per year.(i)
  • Homart Pharmaceuticals Pty Ltd's estimated revenue per employee is $201,000

Employee Data

  • Homart Pharmaceuticals Pty Ltd has 116 Employees.(i)
  • Homart Pharmaceuticals Pty Ltd grew their employee count by 29% last year.

Homart Pharmaceuticals Pty Ltd's People

NameTitleEmail/Phone
1
Founder & CEOReveal Email/Phone
2
Chief Information OfficerReveal Email/Phone
3
General ManagerReveal Email/Phone
4
Group General ManagerReveal Email/Phone
5
National Business ManagerReveal Email/Phone
6
National Business ManagerReveal Email/Phone
7
National Account ManagerReveal Email/Phone
8
Sales Account Manager for contract manufacturing servicesReveal Email/Phone
9
Procurement ManagerReveal Email/Phone
10
Account ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$65.9M3285%N/AN/A
#2
$32.2M1607%N/AN/A
#3
$21.3M1064%N/AN/A
#4
$25.5M12722%N/AN/A
#5
$22.7M1133%N/AN/A
#6
$97.7M48635%N/AN/A
#7
$66.9M3336%N/AN/A
#8
$39.2M19510%N/AN/A
#9
$31.4M1561%N/AN/A
#10
$72.6M3613%N/AN/A
Add Company

What Is Homart Pharmaceuticals Pty Ltd?

Established in 1992, Homart is a leading pharmaceutical company for high quality Australian health supplements, skin care and dairy products. It has been certified by TGA as a cGMP manufacturer with multinational production qualifications such as Europe PIC/s, US.FDA, Halal accreditations and an accredited Australian dairy product manufacturer by China. It has won 16 local and international awards for high quality products and persistent workmanship.

keywords:N/A

N/A

Total Funding

116

Number of Employees

$23.3M

Revenue (est)

29%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$33.2M1232%N/A
#2
$36.3M12526%N/A
#3
$30.6M1288%N/A
#4
$7.5M13713%N/A
#5
$51.5M14215%N/A